REG - Oxford Biomedica PLC - New Project with Orchard Therapeutics

Oxford BioMedicaAnnouncement

26/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220726:nRSZ6888Ta&default-theme=true

RNS Number : 6888T  Oxford Biomedica PLC  26 July 2022

 

 

Oxford Biomedica initiates new project with Orchard Therapeutics utilising
LentiStable™ technology

Oxford, UK - 26 July 2022: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica"
or "the Company"), a leading gene and cell therapy group, today announces that
it has initiated a new project with Orchard Therapeutics utilising the
Company's proprietary LentiStable™ technology.

As part of the project, Oxford Biomedica's LentiStable™ technology platform
will be used to develop a producer cell line capable of stably expressing
lentiviral vectors. Using this technology, the project will be focused on
developing high-performing candidate clones for Orchard Therapeutics' OTL-203,
an investigational hemopoietic stem cell (HSC) gene therapy in development for
the potential treatment of mucopolysaccharidosis type I Hurler's syndrome
(MPS-IH). As part of an existing collaboration, established in November 2016
(https://www.oxb.com/news-media/press-release/oxford-biomedica-announces-strategic-alliance-orchard-therapeutics)
, Orchard Therapeutics will explore the technology to increase the
manufacturing efficiency and scalability of HSC gene therapy.

Oxford Biomedica's cutting edge LentiStable™ technology platform, which is
the result of more than 10 years of optimisation work, allows the development
of a mammalian cell line which can use a chemical inducer to generate viral
vector production without the need for transient transfection. This technology
has the potential to deliver highly efficient producer cell lines to enable
streamlined, scalable and cost-effective manufacturing.

Dr. Kyriacos Mitrophanous, Chief Scientific Officer of Oxford Biomedica,
commented: "We are pleased to enter into a new project with Orchard
Therapeutics, a global gene therapy leader. We are committed to innovation and
to the ongoing development of our platform, which is key to our goal of
widening access to gene therapy by lowering the cost of viral vector
manufacturing. Our proprietary LentiStable™ technology shows great promise
in support of this goal and underlines our overall position as a leader in
cell and gene therapy and our ambition to remain at the forefront of this
important work for patients globally."

Nicoletta Loggia, Ph.D., Chief Technical Officer of Orchard Therapeutics,
added: "This project underscores Orchard's commitment to continued innovation
in all aspects of our operations, including manufacturing. The evaluation of
stable cell producer lines is part of our focus on establishing a sustainable
lentiviral vector manufacturing platform. We look forward to working with
Oxford Biomedica to further explore this technology for the HSC gene therapy
field."

-Ends-

 

Enquiries:

 

Oxford Biomedica plc: T: +44 (0)1865 783 000 / E: ir@oxb.com

 

Stuart Paynter, Chief Financial Officer

Sophia Bolhassan, Head of Investor Relations

 

Consilium Strategic Communications:

T: +44 (0)20 3709 5700 / E: oxfordbiomedica@consilium-comms.com

 

Mary-Jane Elliott / Matthew Neal

 

 

 

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is an innovative leading viral vector specialist
focused on delivering life changing therapies to patients.

 

Oxford Biomedica plc and its subsidiaries (the Group) work across key viral
vector delivery systems including those based on lentivirus, adeno-associated
virus (AAV) and adenovirus, providing innovative solutions to cell and gene
therapy biotechnology and biopharma companies for their process development,
analytical development and manufacturing needs. Oxford Biomedica has built a
sector leading lentiviral vector delivery system, LentiVector® platform,
which the Group leverages to develop product candidates in-house, before
seeking partners to take the products into clinical trials.

 

Oxford Biomedica is based across several locations and is headquartered in
Oxfordshire, UK. In early 2022, the Group established Oxford Biomedica
Solutions, a new US based subsidiary AAV manufacturing and innovation
business, based near Boston, US.

 

Oxford Biomedica employs more than 940 people. Further information is
available at www.oxb.com (http://www.oxb.com) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCEAAXSADLAEAA